Radioactive bullet targets advanced cancers in early trial
NCT ID NCT03746431
Summary
This early-stage study tested a new radioactive drug designed to target and destroy advanced solid tumors. It involved 78 patients with various cancers who had run out of standard treatment options. The main goals were to check the treatment's safety, find the right dose, and see if it showed any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
Centre Hospitalier De I'Universite de Montreal
Montreal, Quebec, H2X 0C1, Canada
-
City of Hope
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Juravinski Cancer Center - Hamilton Health
Hamilton, Ontario, L8V 5C2, Canada
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
Quebec University Hospital- Laval
Québec, Quebec, G1R 2J6, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.